The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
It works by supporting your bodys internal chemistry to favor lighter pigments over darker ones
Taken orally, this diabetes medication is used in conjunction with diet and exercise programs to help regulate glucose levels in the body
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
What to Tell Your Clinician Before Your Steroid Injection Whether you are attending Joint Injection Clinic or any other provider, make sure you tell your clinician: The name and dose of your GLP-1 medication (Mounjaro or Ozempic) Whether you have type 2 diabetes or any other metabolic condition Whether you also take insulin The last date you took your weight loss injection Any previous reactions to steroid injections This allows your clinician to tailor the procedure, choose the most appropriate steroid preparation, provide the right post-injection advice, and flag anything to your GP or diabetes team if necessary
/assets/docs/446094.jpg)
